Intracellular macromolecules in hypoxic cells

Intracellular macromolecules in hypoxic cells serve as the primary molecular targets for hypoxia-activated prodrugs (HAPs) and bioreductive imaging agents [RadiologyKey, ResearchGate]. In the low-oxygen environment characteristic of solid tumors or ischemic tissues, these compounds undergo enzymatic reduction by intracellular reductases to form highly reactive intermediates, such as nitro radicals or hydroxylamines [MDPI, RSC]. In the absence of oxygen, these intermediates cannot be re-oxidized and instead form stable covalent adducts with various cellular components, including DNA, RNA, and thiol-containing proteins [RadiologyKey, AHA Journals]. This process, often referred to as metabolic trapping, allows for the selective accumulation of diagnostic tracers like pimonidazole and [18F]fluoromisonidazole (FMISO), which can be visualized via immunohistochemistry or PET imaging to quantify tissue hypoxia [AACR Journals, MDPI]. Therapeutically, the covalent modification of these macromolecules—particularly the induction of double-strand DNA breaks by agents like tirapazamine or alkylation by evofosfamide—triggers selective cell death in the treatment-resistant hypoxic core of tumors [NIH, ACS]. This mechanism provides a unique strategy to target cells that are typically resistant to conventional radiotherapy and chemotherapy due to their low oxygenation and slow proliferation [RadiologyKey, NIH].

Other names

Hypoxic cell macromoleculesCellular macromoleculesNitroimidazole binding sitesBioreductive drug targets

Bioreductive activation by intracellular reductases (such as NADPH-cytochrome P450 reductase or NQO1) in low-oxygen environments to form reactive intermediates (e.g., nitro radicals, hydroxylamines) that covalently bind to DNA, RNA, and proteins, leading to metabolic trapping or cytotoxicity [RadiologyKey, MDPI, RSC].